First-line Nivolumab + Ipilimumab Superior to Chemotherapy in Metastatic NSCLC at 6 Years

Study Shows Exhaled Breath May Track Treatment Response in Mesothelioma

IASLC’s New 5-Year Strategic Plan Unveiled at Business Meeting

Modified Lung Cancer Screening Eligibility Requirements May Reduce Racial Disparities in Lung Cancer Screening, Treatment

Debaters Argue Merits of Surgery in Malignant Meso in Light of MARS2 Data

Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question

Experts Debate Addition of Frontline Chemotherapy for EGFR+ NSCLC

Should Biomarkers Be Used in the Clinical Management of ES-SCLC?

FLAURA 2 Post-progression Outcomes Demonstrate Consistent Benefit, Favor Combination Arm

MARIPOSA-2 Post-progression Analysis Favors Amivantamab-Chemotherapy Combination

Can Artificial Intelligence Identify Those at High Risk and Shift the Lung Cancer Screening Paradigm?

WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers